Research Analysts Set Expectations for ACTU Q3 Earnings

Key Points

• B. Riley predicts Actuate Therapeutics will report earnings of ($0.29) per share for Q3 2025, maintaining a "Buy" rating with a target price of $20.00.
• Actuate Therapeutics' shares have seen fluctuations, with a twelve-month low of $5.47 and a high of $11.99.
• Recent insider activity includes a significant increase in holdings, with directors purchasing 214,284 shares of the company stock in the past 90 days.

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Equities research analysts at B. Riley issued their Q3 2025 earnings per share estimates for shares of Actuate Therapeutics in a report issued on Monday, August 25th. B. Riley analyst M. Mamtani expects that the company will post earnings of ($0.29) per share for the quarter. B. Riley currently has a "Buy" rating and a $20.00 target price on the stock. B. Riley also issued estimates for Actuate Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.83) EPS and FY2029 earnings at $0.01 EPS.

A number of other analysts have also weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Actuate Therapeutics in a research report on Monday, August 18th. Wall Street Zen downgraded Actuate Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $20.33.

Actuate Therapeutics Trading Down 1.7%

ACTU stock opened at $8.05 on Thursday. Actuate Therapeutics has a twelve month low of $5.47 and a twelve month high of $11.99. The firm's fifty day simple moving average is $7.06 and its two-hundred day simple moving average is $7.92.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock worth $93,000 after purchasing an additional 15,267 shares during the period. Voss Capital LP grew its position in shares of Actuate Therapeutics by 101.0% during the 2nd quarter. Voss Capital LP now owns 286,140 shares of the company's stock worth $1,748,000 after buying an additional 143,759 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of Actuate Therapeutics during the second quarter valued at $105,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of Actuate Therapeutics by 492.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company's stock valued at $113,000 after buying an additional 15,393 shares during the period. Finally, BIOS Capital Management LP raised its holdings in shares of Actuate Therapeutics by 0.7% in the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company's stock valued at $60,887,000 after acquiring an additional 71,428 shares in the last quarter.

Insider Activity at Actuate Therapeutics

In related news, Director Equity Cof Lp Bios bought 71,428 shares of Actuate Therapeutics stock in a transaction dated Friday, June 27th. The shares were acquired at an average cost of $7.00 per share, with a total value of $499,996.00. Following the completion of the transaction, the director owned 196,428 shares in the company, valued at $1,374,996. The trade was a 57.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Aaron G.L. Fletcher purchased 71,428 shares of the firm's stock in a transaction dated Friday, June 27th. The shares were bought at an average cost of $7.00 per share, with a total value of $499,996.00. Following the purchase, the director directly owned 196,428 shares of the company's stock, valued at approximately $1,374,996. This represents a 57.14% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 214,284 shares of company stock worth $1,499,988 in the last 90 days. 69.34% of the stock is owned by corporate insiders.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.